Observation of Progynova in Perimenopausal Syndrome and Effect on Bone Mineral Density
HE Ming-xian
Abstract：Objective To study the effect of progynova on perimenopausal syndrome and bone mineral density. Methods 80 female patients with perimenopausal syndrome were included in the study, and randomly divided into control group (n=40) and observation group (n=40). The patients in the control group had oral calcium carbonate D3 tablets and dydrogesterone, while the observation group took Progynova based on treatment of the control group, and then the improve-ments of perimenopausal syndrome symptoms and the changes of bone mineral density before the treatment, 6 months and 12 months after the treatment were observed. Results 6 months after the treatment, the Greene scores of the two groups were both decreased, the differences when compared with that before the treatment in the two groups showed statistical significance (P<0. 05), but Greene scores of both groups showed no statistical differences (P>0. 05). 12 months and 6 months after treatment, the intra-group comparison and comparison among groups were of statistical significance (P<0. 05). 6 months af-ter the treatment, the spine and femoral neck bone mineral density of the two groups were of statistically significant differences compared to that before the treatment ( P <0. 05 ) , the comparison among groups was of no statistical significance ( P >0. 05 ) . 12 months after treatment, the bone mineral density concentration was higher than that after 6 months, the intra-group comparison and comparison among groups were of statistical significance differences ( P<0. 05 ) . 6 months after treatment, the comparison of E2 and FSH concentration between the two groups were of no significant differences ( P>0. 05 ) , only the changes of progesterone were of statistical differences compared to that before the treatment ( P<0. 05 ); the comparison of FSH, E2, oestrone levels in the two groups were of significant differences between 6 months and 12 months after treatment (P<0. 05), the comparison among the groups was also of statistically significant differences (P<0. 05). Correlation analysis revealed that the expressions of FSH, E2 and progesterone level were correlated with BMD, including negative correlation be-tween FSH and BMD, while E2, progesterone had positive correlation with BDM. Conclusion Hormone level disorder exists in perimenopausal syndrome and bone mass loss. Progynova can significant improve the symptoms of the perimenopausal syn-drome and bone mineral density.
Keywords：PerimenopausalBone mineral densityProgynova
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 92-95 )